Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Structure-Guided Enhancement of Selectivity of Chemical Probe Inhibitors Targeting Bacterial Seryl-tRNA Synthetase.

Cain R, Salimraj R, Punekar AS, Bellini D, Fishwick CWG, Czaplewski L, Scott DJ, Harris G, Dowson CG, Lloyd AJ, Roper DI.

J Med Chem. 2019 Nov 14;62(21):9703-9717. doi: 10.1021/acs.jmedchem.9b01131. Epub 2019 Nov 5.

PMID:
31626547
2.

Evaluation of a Library of FDA-Approved Drugs for Their Ability To Potentiate Antibiotics against Multidrug-Resistant Gram-Negative Pathogens.

Hind CK, Dowson CG, Sutton JM, Jackson T, Clifford M, Garner RC, Czaplewski L.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00769-19. doi: 10.1128/AAC.00769-19. Print 2019 Aug.

3.

Analysis of the clinical antibacterial and antituberculosis pipeline.

Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, Moja L, Paul M, Paulin S, Rex JH, Silver LL, Spigelman M, Thwaites GE, Paccaud JP, Harbarth S.

Lancet Infect Dis. 2019 Feb;19(2):e40-e50. doi: 10.1016/S1473-3099(18)30513-9. Epub 2018 Oct 15. Review.

PMID:
30337260
4.

Discovery and development of new antibacterial drugs: learning from experience?

Jackson N, Czaplewski L, Piddock LJV.

J Antimicrob Chemother. 2018 Jun 1;73(6):1452-1459. doi: 10.1093/jac/dky019. Review.

PMID:
29438542
6.

Alternatives to antibiotics-a pipeline portfolio review.

Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Ólafsdóttir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH.

Lancet Infect Dis. 2016 Feb;16(2):239-51. doi: 10.1016/S1473-3099(15)00466-1. Epub 2016 Jan 13. Review.

PMID:
26795692
7.

Eliminating Extravasation Events: A Multidisciplinary Approach.

Coyle CE, Griffie J, Czaplewski LM.

J Infus Nurs. 2015 Nov-Dec;38 Suppl 6:S43-50. doi: 10.1097/NAN.0000000000000144.

PMID:
26536412
8.

Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: structure based design, synthesis, SAR and antimicrobial activity.

Yule IA, Czaplewski LG, Pommier S, Davies DT, Narramore SK, Fishwick CW.

Eur J Med Chem. 2014 Oct 30;86:31-8. doi: 10.1016/j.ejmech.2014.08.025. Epub 2014 Aug 7.

9.

Eliminating extravasation events: a multidisciplinary approach.

Coyle CE, Griffie J, Czaplewski LM.

J Infus Nurs. 2014 May-Jun;37(3):157-64. doi: 10.1097/NAN.0000000000000034.

PMID:
24694509
10.

Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ.

Stokes NR, Baker N, Bennett JM, Chauhan PK, Collins I, Davies DT, Gavade M, Kumar D, Lancett P, Macdonald R, Macleod L, Mahajan A, Mitchell JP, Nayal N, Nayal YN, Pitt GR, Singh M, Yadav A, Srivastava A, Czaplewski LG, Haydon DJ.

Bioorg Med Chem Lett. 2014 Jan 1;24(1):353-9. doi: 10.1016/j.bmcl.2013.11.002. Epub 2013 Nov 13.

PMID:
24287381
11.

Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors.

Axford LC, Agarwal PK, Anderson KH, Andrau LN, Atherall J, Barker S, Bennett JM, Blair M, Collins I, Czaplewski LG, Davies DT, Gannon CT, Kumar D, Lancett P, Logan A, Lunniss CJ, Mitchell DR, Offermann DA, Palmer JT, Palmer N, Pitt GR, Pommier S, Price D, Narasinga Rao B, Saxena R, Shukla T, Singh AK, Singh M, Srivastava A, Steele C, Stokes NR, Thomaides-Brears HB, Tyndall EM, Watson D, Haydon DJ.

Bioorg Med Chem Lett. 2013 Dec 15;23(24):6598-603. doi: 10.1016/j.bmcl.2013.10.058. Epub 2013 Nov 4.

PMID:
24239017
12.

Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.

Stokes NR, Thomaides-Brears HB, Barker S, Bennett JM, Berry J, Collins I, Czaplewski LG, Gamble V, Lancett P, Logan A, Lunniss CJ, Peasley H, Pommier S, Price D, Smee C, Haydon DJ.

Antimicrob Agents Chemother. 2013 Dec;57(12):5977-86. doi: 10.1128/AAC.00719-13. Epub 2013 Sep 16.

13.

An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy.

Stokes NR, Baker N, Bennett JM, Berry J, Collins I, Czaplewski LG, Logan A, Macdonald R, Macleod L, Peasley H, Mitchell JP, Nayal N, Yadav A, Srivastava A, Haydon DJ.

Antimicrob Agents Chemother. 2013 Jan;57(1):317-25. doi: 10.1128/AAC.01580-12. Epub 2012 Oct 31.

14.

Correlating novice nurses' perceptions of nursing orientation and first-year support with direct preceptor interventions.

Nelson JL, Arjes M, Bushman K, Carlson M, Czaplewski L, Derby K, Godman K, Horton D, Stansfield T, Tan HP.

J Contin Educ Nurs. 2012 Feb;43(2):59-64; quiz 65-6. doi: 10.3928/00220124-20120125-13.

PMID:
22313130
15.

Searching the literature: a researcher's perspective.

Czaplewski LM.

J Infus Nurs. 2012 Jan-Feb;35(1):20-6. doi: 10.1097/NAN.0b013e31823cd036. Review.

PMID:
22222288
16.

Multiple effects of benzamide antibiotics on FtsZ function.

Adams DW, Wu LJ, Czaplewski LG, Errington J.

Mol Microbiol. 2011 Apr;80(1):68-84. doi: 10.1111/j.1365-2958.2011.07559.x. Epub 2011 Feb 15.

17.

Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties.

Haydon DJ, Bennett JM, Brown D, Collins I, Galbraith G, Lancett P, Macdonald R, Stokes NR, Chauhan PK, Sutariya JK, Nayal N, Srivastava A, Beanland J, Hall R, Henstock V, Noula C, Rockley C, Czaplewski L.

J Med Chem. 2010 May 27;53(10):3927-36. doi: 10.1021/jm9016366.

18.

DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.

East SP, White CB, Barker O, Barker S, Bennett J, Brown D, Boyd EA, Brennan C, Chowdhury C, Collins I, Convers-Reignier E, Dymock BW, Fletcher R, Haydon DJ, Gardiner M, Hatcher S, Ingram P, Lancett P, Mortenson P, Papadopoulos K, Smee C, Thomaides-Brears HB, Tye H, Workman J, Czaplewski LG.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):894-9. doi: 10.1016/j.bmcl.2008.11.102. Epub 2008 Dec 3. Erratum in: Bioorg Med Chem Lett. 2009 May 1;19(9):2606.

PMID:
19095445
19.

Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.

Czaplewski LG, Collins I, Boyd EA, Brown D, East SP, Gardiner M, Fletcher R, Haydon DJ, Henstock V, Ingram P, Jones C, Noula C, Kennison L, Rockley C, Rose V, Thomaides-Brears HB, Ure R, Whittaker M, Stokes NR.

Bioorg Med Chem Lett. 2009 Jan 15;19(2):524-7. doi: 10.1016/j.bmcl.2008.11.021. Epub 2008 Nov 13.

PMID:
19064318
20.

An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.

Haydon DJ, Stokes NR, Ure R, Galbraith G, Bennett JM, Brown DR, Baker PJ, Barynin VV, Rice DW, Sedelnikova SE, Heal JR, Sheridan JM, Aiwale ST, Chauhan PK, Srivastava A, Taneja A, Collins I, Errington J, Czaplewski LG.

Science. 2008 Sep 19;321(5896):1673-5. doi: 10.1126/science.1159961.

21.

Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement.

Chopra I, Schofield C, Everett M, O'Neill A, Miller K, Wilcox M, Frère JM, Dawson M, Czaplewski L, Urleb U, Courvalin P.

Lancet Infect Dis. 2008 Feb;8(2):133-9. doi: 10.1016/S1473-3099(08)70018-5.

PMID:
18222164
22.

Essential bacterial functions encoded by gene pairs.

Thomaides HB, Davison EJ, Burston L, Johnson H, Brown DR, Hunt AC, Errington J, Czaplewski L.

J Bacteriol. 2007 Jan;189(2):591-602. Epub 2006 Nov 17.

23.

Pathways to excellence.

Czaplewski LM.

J Infus Nurs. 2006 Jul-Aug;29(4):204-5. No abstract available.

PMID:
16858252
24.

Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay.

Stokes NR, Sievers J, Barker S, Bennett JM, Brown DR, Collins I, Errington VM, Foulger D, Hall M, Halsey R, Johnson H, Rose V, Thomaides HB, Haydon DJ, Czaplewski LG, Errington J.

J Biol Chem. 2005 Dec 2;280(48):39709-15. Epub 2005 Sep 20.

25.

Managing complications of midlines and PICCs.

Gorski LA, Czaplewski LM.

Nursing. 2005 Jun;35(6):68-9. No abstract available.

PMID:
15931129
26.

Peripherally inserted central catheters and midline catheters for the homecare nurse.

Gorski LA, Czaplewski LM.

J Infus Nurs. 2004 Nov-Dec;27(6):399-409; quiz 410-2. Review.

PMID:
15586103
27.

Peripherally inserted central & midline catheters for the home care nurse.

Gorski LA, Czaplewski LM.

Home Healthc Nurse. 2004 Nov;22(11):758-71; quiz 772-3. Review. No abstract available.

PMID:
15586058
28.

Test your knowledge: technology and clinical applications.

Czaplewski LM.

J Infus Nurs. 2003 Jan-Feb;26(1):11-2. No abstract available.

PMID:
12544362
29.

Chemical modification of a variant of human MIP-1alpha; implications for dimer structure.

Ashfield JT, Meyers T, Lowne D, Varley PG, Arnold JR, Tan P, Yang JC, Czaplewski LG, Dudgeon T, Fisher J.

Protein Sci. 2000 Oct;9(10):2047-53.

30.

Identification and characterization of a rat macrophage inflammatory protein-1alpha receptor.

Waller A, Nayee P, Czaplewski LG.

J Hematother Stem Cell Res. 2000 Oct;9(5):703-9.

PMID:
11091494
31.

RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation.

Appay V, Dunbar PR, Cerundolo V, McMichael A, Czaplewski L, Rowland-Jones S.

Int Immunol. 2000 Aug;12(8):1173-82.

PMID:
10917892
32.

Aggregation of RANTES is responsible for its inflammatory properties. Characterization of nonaggregating, noninflammatory RANTES mutants.

Appay V, Brown A, Cribbes S, Randle E, Czaplewski LG.

J Biol Chem. 1999 Sep 24;274(39):27505-12.

33.

Marketing your expertise.

Czaplewski LM.

J Intraven Nurs. 1999 Mar-Apr;22(2):75-80. Review.

PMID:
10418410
35.

Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants.

Czaplewski LG, McKeating J, Craven CJ, Higgins LD, Appay V, Brown A, Dudgeon T, Howard LA, Meyers T, Owen J, Palan SR, Tan P, Wilson G, Woods NR, Heyworth CM, Lord BI, Brotherton D, Christison R, Craig S, Cribbes S, Edwards RM, Evans SJ, Gilbert R, Morgan P, Randle E, Schofield N, Varley PG, Fisher J, Waltho JP, Hunter MG.

J Biol Chem. 1999 Jun 4;274(23):16077-84.

36.

Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010.

Marshall E, Howell AH, Powles R, Hunter MG, Edwards M, Wood LM, Czaplewski L, Puttick R, Warrington S, Boyce M, Testa N, Dexter TM, Lord BI, Millar A.

Eur J Cancer. 1998 Jun;34(7):1023-9.

PMID:
9849450
37.

A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy.

Clemons MJ, Marshall E, Dürig J, Watanabe K, Howell A, Miles D, Earl H, Kiernan J, Griffiths A, Towlson K, DeTakats P, Testa NG, Dougal M, Hunter MG, Wood LM, Czaplewski LG, Millar A, Dexter TM, Lord BI.

Blood. 1998 Sep 1;92(5):1532-40.

PMID:
9716580
38.

The growth inhibitory role and potential clinical value of macrophage inflammatory protein 1 alpha in myeloid leukaemias.

Owen-Lynch PJ, Czaplewski LG, Hunter MG, Whetton AD.

Leuk Lymphoma. 1998 Jun;30(1-2):41-53. Review.

PMID:
9669675
39.

Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha.

Wark G, Heyworth CM, Spooncer E, Czaplewski L, Francis JM, Dexter TM, Whetton AD.

Oncogene. 1998 Mar 12;16(10):1319-24.

40.

The effects of human macrophage inflammatory protein-1 alpha and its genetically modified variant, BB10010, on phagocyte function.

Williams SL, Addison IE, Mollapour E, Czaplewski LG, Linch DC, Roberts PJ.

Cytokines Cell Mol Ther. 1997 Mar;3(1):41-50.

PMID:
9287243
41.

Assays for macrophage inflammatory proteins.

Buckle AM, Craig S, Czaplewski LG.

Methods Enzymol. 1997;287:127-48. No abstract available.

PMID:
9330319
42.

The effect of the chemokine rhMIP-1 alpha, and a non-aggregating variant BB-10010, on blast cells from patients with acute myeloid leukaemia.

Owen-Lynch PJ, Adams JA, Brereton ML, Czaplewski LG, Whetton AD, Yin JA.

Br J Haematol. 1996 Oct;95(1):77-84.

PMID:
8857942
43.

BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties.

Hunter MG, Bawden L, Brotherton D, Craig S, Cribbes S, Czaplewski LG, Dexter TM, Drummond AH, Gearing AH, Heyworth CM, Lord BI, McCourt M, Varley PG, Wood LM, Edwards RM, Lewis PJ.

Blood. 1995 Dec 15;86(12):4400-8.

PMID:
8541527
44.

Mobilization of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha.

Lord BI, Woolford LB, Wood LM, Czaplewski LG, McCourt M, Hunter MG, Edwards RM.

Blood. 1995 Jun 15;85(12):3412-5.

PMID:
7540061
45.

Purification and initial characterization of AhrC: the regulator of arginine metabolism genes in Bacillus subtilis.

Czaplewski LG, North AK, Smith MC, Baumberg S, Stockley PG.

Mol Microbiol. 1992 Jan;6(2):267-75.

PMID:
1312212
46.

Crystallization of the arginine-dependent repressor/activator AhrC from Bacillus subtilis.

Boys CW, Czaplewski LG, Phillips SE, Baumberg S, Stockley PG.

J Mol Biol. 1990 May 20;213(2):227-8.

PMID:
2111409
47.

Sequences required for regulation of arginine biosynthesis promoters are conserved between Bacillus subtilis and Escherichia coli.

Smith MC, Czaplewski L, North AK, Baumberg S, Stockley PG.

Mol Microbiol. 1989 Jan;3(1):23-8.

PMID:
2497296

Supplemental Content

Loading ...
Support Center